Referencia número: HY-122022

JR-AB2-011

20 Cited Publications

Revisión del cliente

Based on 20 publication(s) in Google Scholar

JR-AB2-011 is a selective mTORC2 inhibitor with an IC₅₀ value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (K_i: 0.19 μM).JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.15%
No. CAS: 2411853-34-2
Fòrmula: C₁₇H₁₄Cl₂FN₃OS
Peso molecular:398.28

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

JR-AB2-011 Chemical Structure

No. CAS: 2411853-34-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (20)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

JR-AB2-011 is a selective mTORC2 inhibitor with an IC₅₀ value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (K_i: 0.19 μM)^[1].JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death^[2].

IC₅₀ & Target^[1]

mTORC2

0.36 μM (IC₅₀)

Ver todos los productos específicos de isoformas mTOR :

In Vitro

JR-AB2-011 (10 µM - 250 µM; 48h) significantly reduces the survival rate and proliferation ability of different melanoma cell lines (MelJu, MelJuso, MelIm, B16)^[2].
JR-AB2-011 (50 µM, 250 µM; 48 h) decreases the phosphorylation level of Akt in MelIm cells, indicating that inhibition of mTORC2 attenuated the Ak t signaling pathway^[2].
JR-AB2-011 (50 µM, 250 µM; 48-78 h) results in a significant decrease in cell survival fraction SF and a significant reduction in the migration and invasive ability of melanoma cells, which is mainly achieved by decreasing MMP2 activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

MelJuso
Concentration:

50 µM, 250 µM
Incubation Time:

72h
Result:

JR-AB2-011 significantly reduced MMP2 protein and inhibited MMP2 activity, thereby inhibiting tumor cell invasion.

In Vivo

JR-AB2-011 (20 mg/kg; i.p.; daily) reduces the size and number of liver metastases in C57BL/6N mice with injection of B16 cells. No severe side effects or weight loss^[2].
JR-AB2-011 (4 mg/kg; p.o.; daily) significantly blocks the Dioscin-induced promotion of M2 macrophage polarization^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N mice with injection of B16 cells ^[2].
Dosage:

20 mg/kg everyday
Administration:

i.p.
Result:

JR-AB2-011 resulted in a significant decrease in hepatic tumor burden and metastasis load, as assessed by MRI and BLI.
Histological analysis confirmed the presence of fewer and smaller metastases in the liver of treated mice. MMP2 expression was also significantly reduced.

Animal Model:

DSS (dextran sulfate sodium) induced colitis in mice ^[3]
Dosage:

4 mg/kg; Dioscin 160 mg/kg; daily
Administration:

p.o.
Result:

JR-AB2-011 significantly blocked the Dioscin-induced promotion of M2 macrophage polarization.
JR-AB2-011 inhibited the mTORC2/PPAR-γ signaling pathway, attenuating the regulatory effects of Dioscin on macrophage metabolism and polarization.
The decrease in inflammation-related biomarkers (e.g., TNF-α, IL-6, IFN-γ, etc.) was partially reversed, indicating that the anti-inflammatory effects of Dioscin were suppressed.

Chemical Information

No. CAS 2411853-34-2
Appearance Solid
Peso molecular 398.28
Fòrmula C₁₇H₁₄Cl₂FN₃OS
Color White to off-white
SMILES

ClC1=C(Cl)C=C(NC(N2/C(SC(C)C2)=N/C3=CC=C(F)C=C3)=O)C=C1
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (20)

All OthersCell Imaging/StainingWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Cell

Stromal lipid species dictate melanoma metastasis and tropism. [Abstract]

2025 Apr 22:S1535-6108(25)00138-2. PMID: 40280124

JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Apr 22:S1535-6108(25)00138-2. [Abstract]

Relative proliferation of A375 cells treated with young adipocyte secretome (YA, blue) or YA with 500nM mTORC2 inhibitor JR-AB2-011 (YA+JR-AB2-011, white square with blue outline) or control (black) for 48 hours.
Nat Cell Biol

Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint. [Abstract]

2025 Jan;27(1):73-86. PMID: 39779939

JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Jan;27(1):73-86. [Abstract]

Immunofluorescence staining results of p21 cells in G1 phase RPE-1 cells after treatment with mTORC1/2 inhibitor INK-128 (0.2 μM), mTORC2 inhibitor JR-AB2-011 (5 μM), or mTORC1 inhibitor rapamycin (0.1 μM) for 24 hours.
J Extracell Vesicles

CD24 Regulates the Formation of Ectosomes in B Lymphocytes. [Abstract]

2025 May;14(5):e70093. PMID: 40415253

JR-AB2-011 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2025 May;14(5):e70093. [Abstract]

WEHI-231-GFP cells were pretreated with Torin 1, rapamycin, JR-AB2-011 (0.1 µM), or DMSO for 15 minutes, then stimulated with anti-CD24 antibody or isotype control antibody for 15 minutes, followed by elution and co-culture with WEHI-303-tdTomato cells for 24 hours. The percentage of GFP and tdTomato double-positive cells was recorded after 24 hours of incubation.
Nat Commun

The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. [Abstract]

2026 Jan 20;17(1):614. PMID: 41559041

JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 20;17(1):614. [Abstract]

Representative images of BODIPY staining in the indicated cells treated with Vehicle (DMSO), 50 μM JR-AB2-011 for 48 hours and 1 mM sodium citrate for 12 hours before harvest.
Sci Immunol

SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors. [Abstract]

2022 Jan 21;7(67):eabj5501. PMID: 35061505
Cell Rep Med

CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. [Abstract]

2024 Dec 17;5(12):101844. PMID: 39637858

JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Dec 17;5(12):101844. [Abstract]

IB analysis was performed on three different GSCs (83, X01, and 528 cells) to detect the levels of p-S6K, p-AKT, S6K, AKT, ARHGAP1, BZW1, and BZW2, after these cells were treated with JR-AB2-011 for 24 hours.
Cell Death Dis

miR-582 negatively regulates pre-B cell proliferation and survival through targeting Hif1α and Rictor. [Abstract]

2022 Feb 3;13(2):107. PMID: 35115499
Pharmacol Res

Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. [Abstract]

2021 Oct:172:105796. PMID: 34343656
J Exp Med

Somatic gain-of-function mutations in BUD13 promote oncogenesis by disrupting Fbw7 function. [Abstract]

2023 Oct 2;220(10):e20222056. PMID: 37382881
Int Immunopharmacol

Glucocorticoid signaling mitigates colitis-associated visceral hypersensitivity by suppressing 5-HT release in enterochromaffin cells via a GR-PI3K-SGK1 axis. [Abstract]

2026 Mar 1:172:116207. PMID: 41554225
Int J Mol Sci

A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. [Abstract]

2021 Apr 21;22(9):4322. PMID: 33919246
Front Pharmacol

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]

2020 Nov 11:11:580407. PMID: 33343350
Pharmacol Rep

JR-AB2-011 induces fast metabolic changes independent of mTOR complex 2 inhibition in human leukemia cells. [Abstract]

2024 Dec;76(6):1390-1402. PMID: 39259491
Biomedicines

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy. [Abstract]

2021 Oct 19;9(10):1498. PMID: 34680615
Front Mol Biosci

FLCN Regulates HIF2α Nuclear Import and Proliferation of Clear Cell Renal Cell Carcinoma. [Abstract]

2020 Jul 28;7:121. PMID: 32850947
Biology (Basel)

SLC16a6, mTORC1, and Autophagy Regulate Ketone Body Excretion in the Intestinal Cells. [Abstract]

2023 Nov 26;12(12):1467. PMID: 38132294
Epilepsy Res

Inhibition of mTORC2 improves brain injury in epileptic rats by promoting chaperone-mediated autophagy. [Abstract]

2023 Jul:193:107161. PMID: 37163909
bioRxiv

2024 August 14.
Res Sq

2024 Jul 15.
bioRxiv

2024 Apr 3.

Solvente y solubilidad

In Vitro:

DMSO : 62.5 mg/mL (156.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5108 mL

12.5540 mL

25.1080 mL

5 mM

0.5022 mL

2.5108 mL

5.0216 mL

10 mM

0.2511 mL

1.2554 mL

2.5108 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (282 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Zhang A, et al. CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke Vasc Neurol. 2022 Jul 26;8(1):4–16. [Content Brief]

[2]. Guenzle J, et al. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int J Mol Sci. 2020 Dec 22;22(1):30

[3]. Wu M, et al Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021 Oct ; 172:105796 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5108 mL	12.5540 mL	25.1080 mL	62.7699 mL
	5 mM	0.5022 mL	2.5108 mL	5.0216 mL	12.5540 mL
	10 mM	0.2511 mL	1.2554 mL	2.5108 mL	6.2770 mL
	15 mM	0.1674 mL	0.8369 mL	1.6739 mL	4.1847 mL
	20 mM	0.1255 mL	0.6277 mL	1.2554 mL	3.1385 mL
	25 mM	0.1004 mL	0.5022 mL	1.0043 mL	2.5108 mL
	30 mM	0.0837 mL	0.4185 mL	0.8369 mL	2.0923 mL
	40 mM	0.0628 mL	0.3138 mL	0.6277 mL	1.5692 mL
	50 mM	0.0502 mL	0.2511 mL	0.5022 mL	1.2554 mL
	60 mM	0.0418 mL	0.2092 mL	0.4185 mL	1.0462 mL
	80 mM	0.0314 mL	0.1569 mL	0.3138 mL	0.7846 mL
	100 mM	0.0251 mL	0.1255 mL	0.2511 mL	0.6277 mL

Keywords

JR-AB2-011

20 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

JR-AB2-011

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Anti-Infection Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) JR-AB2-011

Ver todos los productos específicos de isoformas mTOR

Actividad biológica

Chemical Information

Publications (20)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

JR-AB2-011 Related Classifications

HY-122022 Related Classifications